Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
CRISPR Therapeutics AG
Scientific Title
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation